[Ip-health] Gilead´s Tenofovir

Tahir Amin tahir at i-mak.org
Fri Jan 6 13:32:20 PST 2012

Apologies for re-posting, but this is the link to the final report Priti
sent earlier.


---------- Forwarded message ----------
From: Priti Radhakrishnan <priti.radhakrishnan at gmail.com>
Date: 4 January 2012 12:13
Subject: Re: [Ip-health] Gilead´s Tenofovir
To: Francisco Rossi <francisco_rossi at hotmail.com>
Cc: ip-health at lists.keionline.org, frossi at ifarma.org

> Francisco raises some very relevant points in his earlier emails. We need
> to be careful about applauding companies like Gilead Sciences without
> measuring actual contributions for patient access.

> According to Gilead (and now several other stakeholders), the 2006
> licenses on TDF were not severable.  Yet to our knowledge the final 2006
> licenses are not publicly available- so on what basis are these statements
> being made? On Gilead's word?
> According to Gilead, countries excluded from those 2006 licenses could not
> have been supplied by generics who had signed the licenses.
> Some very cursory research uncovered the following:
> Countries such as Georgia, Morocco and the Philippines -- so called 2006
> "excluded territories" -- were being supplied by Matrix, Aurobindo and
> Ranbaxy after 2006 but BEFORE Gilead cut side licenses and entered the
> MPP's Pool in 2011.

Therefore it seems that the original 2006 licenses were not binding in the
> first place. Alternatively, Gilead cut further side deals after 2006 to
> allow its licensees to supply those countries.
> *In other words, Gilead was already unbundling its own licenses.*
> It is surprising to us that so many people are lauding Gilead for a
> phenomenal public relations achievement, where actual measurable
> contributions for patient coverage are missing. It appears, as the old
> goes, that the emperor has no clothes on.

For seven years, many of us on this listserve have been monitoring and
> fighting Gilead's manipulative tactics. We believe this company (and
> others) still require careful monitoring. Our 4 page "unbundling" report
> available here: http://tinyurl.com/72hhgvu.
> Priti Radhakrishnan
> www.i-mak.org
Ip-health mailing list
Ip-health at lists.keionline.org

Tahir Amin
Co-Founder and Director of IP
Initiative for Medicines, Access & Knowledge (I-MAK)
Email: tahir at i-mak.org

More information about the Ip-health mailing list